(R)-1-氯-2-丙醇 | 19141-39-0

• 物质功能分类: 化学试剂 - 手性化学试剂
• 分子结构分类: 有机化合物 - 有机卤素化合物 - 卤代醇
• 中文名称: (R)-1-氯-2-丙醇
• 英文名称: (R)-1-chloro-2-propanol
• 英文别名: (R)-1-chloropropan-2-ol；(2R)-1-chloropropan-2-ol
• CAS: 19141-39-0
• 化学式: C₃H₇ClO
• 分子量: 94.541
• InChiKey: YYTSGNJTASLUOY-GSVOUGTGSA-N

物化性质

• 沸点：
  126.5±0.0 °C(Predicted)
• 密度：
  1.082±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.6
• 重原子数：
  5
• 可旋转键数：
  1
• 环数：
  0.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  1

安全信息

• 海关编码：
  2905590090
• 包装等级：
  II
• 危险类别：
  3
• 危险性防范说明：
  P210,P403+P235
• 危险品运输编号：
  1993
• 危险性描述：
  H225
• 储存条件：
  2-8°C

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: (R)-1-Chloro-2-propanol
Synonyms:

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: (R)-1-Chloro-2-propanol
CAS number: 19141-39-0

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels, refrigerated.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C3H7ClO
Molecular weight: 94.5

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, hydrogen chloride.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  茶碱 、 (R)-1-氯-2-丙醇 在 potassium hydroxide 作用下， 以 水 为溶剂， 反应 24.0h， 生成 7-[(2R)-2-羟基丙基]-1,3-二甲基-3,7-二氢-1H-嘌呤-2,6-二酮
  参考文献：
  名称：

  具有黄嘌呤骨架的药物在水中的（-）-表没食子儿茶素-3-O-没食子酸酯的手性识别。

  摘要：

  在水中具有黄嘌呤骨架，茶碱，茶碱，双茶碱和（-）-表没食子儿茶素3-O-没食子酸酯（EGCg）的药物混合物产生了粘稠的沉淀，该沉淀被认为是药物和EGCg的2：2配合物。通过EGCg对具有黄嘌呤骨架的药物的分子捕获能力通过复合物的沉淀物中包含的药物量来估计，并通过定量1H-NMR谱中的质子信号的积分值来测量。通过添加标准量的EGCg，基于1H-NMR光谱中具有黄嘌呤骨架的药物的质子信号化学位移的变化，认为该药物的黄嘌呤骨架存在于由三种芳香族A，B形成的疏水空间中，EGCg的B'环，疏水性空间之外存在一部分代用碱和双用脯氨酸侧链。在（R）-和（S）-脯氨茶碱，（R）-和（S）-双脯氨酸混合物以及等分子量的EGCg的混合物的1H-NMR光谱中，（R）-和（清楚地观察到S）-氧茶碱，（R）-和（S）-二茶碱为两个单峰。这表明EGCg识别水中的替比林和双茶碱的手性。

  DOI：

  10.1248/cpb.c18-00027
• 作为产物：
  描述：

  1-氯-2-丙醇 生成 (R)-1-氯-2-丙醇
  参考文献：
  名称：

  Enantiomerically enriched bifunctional sec-alcohols prepared by Candida antarctica lipase B catalysis. Evidence of non-steric interactions

  摘要：

  Transesterification catalysed by Candida antarctica lipase B was used for the preparation of enantiomerically enriched bifunctional sec-alcohols. The enantiomeric ratio, E, for 3-butyn-2-ol was increased from 1.3 to over 500 by adding an easily removable protecting group. Kinetic resolution of bromohydrins and chlorohydrins bearing a halogen on the large substituent showed high enantioselectivity (E>80). On the other hand, halohydrins with the halogen on the medium group showed low E. Large differences in enantioselectivity were found by substituting the halogen atom of 1-halo-2-alkanols by a methyl group. These differences corresponded to more than 2 kcal mol(-1) and were ascribed to non-steric interactions. (C) 1997 Elsevier Science Ltd. All rights reserved.

  DOI：

  10.1016/s0957-4166(97)00004-9

文献信息

• [EN] PYRAZOLYLAMINOBENZIMIDAZOLE DERIVATIVES AS JAK INHIBITORS<br/>[FR] DÉRIVÉS DE PYRAZOLYLAMINOBENZIMIDAZOLE EN TANT QU'INHIBITEURS DE JAK
  申请人：LILLY CO ELI

  公开号：WO2018013486A1

  公开（公告）日：2018-01-18

  The present invention provides compounds of the formula below (I'): where R, and R1-R3 are as described herein, methods of treating patients for certain types of autoimmune diseases and cancer, and processes for preparing the compounds.

  本发明提供了以下式(I')的化合物：其中R，R1-R3如本文所述，治疗某些类型的自身免疫疾病和癌症的方法，以及制备这些化合物的方法。
• [EN] 4-METHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTHALENES<br/>[FR] 4-MÉTHYL-2,3,5,9,9B-PENTAAZA-CYCLOPENTA[A]NAPHTALÈNES
  申请人：BOEHRINGER INGELHEIM INT

  公开号：WO2014019979A1

  公开（公告）日：2014-02-06

  The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

  该发明涉及一般式(I)的4-甲基-2,3,5,9,9b-五氮杂-环戊[α]萘衍生物，它们是磷酸二酯酶2和/或10的抑制剂，可用于治疗中枢神经系统疾病和其他疾病。此外，该发明涉及制备药物组合物的方法，以及根据该发明制造化合物的方法。
• 4-Methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalenes
  申请人：GIOVANNINI Riccardo

  公开号：US20140045856A1

  公开（公告）日：2014-02-13

  The invention relates to 4-methyl-2,3,5,9,9b-pentaaza-cyclopenta[a]naphthalene derivatives of general formula (I) which are inhibitors of phosphodiesterase 2 and/or 10, useful in treating central nervous system diseases and other diseases. In addition, the invention relates to processes for preparing pharmaceutical compositions as well as processes for manufacture the compounds according to the invention.

  这项发明涉及一般式(I)的4-甲基-2,3,5,9,9b-五氮杂-环戊[α]萘衍生物，它们是磷酸二酯酶2和/或10的抑制剂，可用于治疗中枢神经系统疾病和其他疾病。此外，该发明涉及制备药物组合物的方法，以及根据该发明制造化合物的方法。
• [EN] BIARYL MONOBACTAM COMPOUNDS AND METHODS OF USE THEREOF FOR THE TREATMENT OF BACTERIAL INFECTIONS<br/>[FR] COMPOSÉS DE BIARYLMONOBACTAME ET PROCÉDÉS D'UTILISATION CORRESPONDANTS POUR LE TRAITEMENT D'INFECTIONS BACTÉRIENNES
  申请人：MERCK SHARP & DOHME

  公开号：WO2017106064A1

  公开（公告）日：2017-06-22

  The present invention relates to biaryl monobactam compounds of Formula I: and pharmaceutically acceptable salts thereof, wherein X, Y, Z, A1, Q, A2, M, W, RX and Rz are as defined herein. The present invention also relates to compositions which comprise a biaryl monobactam compound of the invention or a pharmaceutically acceptable salt therof, and a pharmaceutically acceptable carrier. The invention further relates to methods for treating a bacterial infection comprising administering to the patient a therapeutically effective amount of a compound of the invention, either alone or in combination with a therapeutically effective amount of a second beta-lactam antibiotic.

  本发明涉及公式I的联苯单环内酰胺化合物及其药学上可接受的盐，其中X、Y、Z、A1、Q、A2、M、W、RX和Rz如本文所定义。本发明还涉及包含本发明的联苯单环内酰胺化合物或其药学上可接受的盐以及药学上可接受的载体的组合物。该发明还涉及治疗细菌感染的方法，包括向患者施用本发明化合物的治疗有效量，单独或与第二种β-内酰胺类抗生素的治疗有效量结合。
• NOVEL HETEROCYCLIC COMPOUNDS AND USE THEREOF IN MEDICINE AND IN COSMETICS
  申请人：GALDERMA RESEARCH & DEVELOPMENT

  公开号：US20180050992A1

  公开（公告）日：2018-02-22

  The invention relates to novel heterocyclic compounds of general formula (I), as well as their pharmaceutically acceptable salts, and their enantiomers. The invention also relates to the use thereof as a medicinal product, preferably in the prevention and/or treatment of inflammatory diseases with a neurogenic component or use thereof as a cosmetic. The compounds of the present invention act as antagonists of the CGRP-R receptor.

  这项发明涉及一般式(I)的新型杂环化合物，以及它们的药用盐和对映体。该发明还涉及将其用作药物产品，优选用于预防和/或治疗具有神经源性成分的炎症性疾病，或将其用作化妆品。本发明的化合物作为CGRP-R受体的拮抗剂。